Nov 20 2009
RaySearch Laboratories (STO:RAYB): JANUARY 1 – SEPTEMBER, 30 2009
• Net sales for the period amounted to SEK 47.3 M (41.3)
• Profit after tax was SEK 12.6 M (7.3) and earnings per share amounted to SEK 0.37 (0.21)
• Operating profit was SEK 17.1 M (8.0)
• Cash flow totaled SEK 5.4 M (neg: 20.0)
• The first product from the collaboration with TomoTherapy received FDA clearance in January and has been launched
• Three products from the collaboration with Varian were launched in June
• Breakthrough order for proton treatment planning system was secured in June
• Two new products from the collaboration with Nucletron were launched in September
AFTER THE END OF THE PERIOD
• The new VMAT product from the collaboration with Philips began generating revenues in November
• The collaboration agreement with Siemens, which was signed in May, was expanded and accelerated in November
“It is extremely satisfying that the major development efforts during recent years are now beginning to pay off. In November our new product for Philips started generating revenues and we anticipate that the total revenue contribution from this and other new products will exceed SEK 10 M already in the fourth quarter,” says Johan Löf, President of RaySearch.
“We have also expanded and accelerated our collaboration with Siemens which is now expected to start generating revenues in the second half of 2010 instead of in 2011 as previously stated. Consequently, I can say that the potential for growth has never looked as favorable as it does now,” concludes Johan Löf.